Rezatapopt not checked
PMV Pharmaceuticals, Inc · PC14586
FollowEvery change as it happens, and a Monday email
Trials
2 active
6 in total · 1 in the EU
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “First-in-class, oral, small molecule p53 reactivator selective for the TP53 Y220C mutation.”In the company’s words, NCT04585750 on ClinicalTrials.gov
- Tested for
- Advanced Solid Tumor, Advanced Malignant Neoplasm, Metastatic Cancer, Metastatic Solid Tumor, Lung Cancer, Ovarian Cancer, Endometrial Cancer, Prostate Cancer and 24 more
- Main trialPhase 1/2
- “The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. The Phase 1 portion of the study will assess the safety, tolerability and preliminary efficacy of multiple dose levels of rezatapopt as monotherapy and in Phase 1b in combination with pembrolizumab.”In the company’s words, NCT04585750 on ClinicalTrials.gov
- Other names
- PC14586
Other drugs for Advanced Solid Tumor
- AvelumabEMD Serono Research & Development Institute, Inc. · Phase 3
- AlectinibRoche · Phase 3
- AtezolizumabRoche · Phase 3
- AU-011Aura Biosciences · Phase 3
- BevacizumabRoche · Phase 3
- CadonilimabAkeso · Phase 3
Coming up2
- 15 DecPhase 1/2 trial completes · ClinicalTrials.gov
- Mar 2027Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials6
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Recruiting | 15 Dec 2026 | The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) | |
| Phase 1Recruiting | Mar 2027 | A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation. | |
| Phase 1Completed | 9 Jun 2022 | Effect of Food on PC14586 in Healthy Volunteers and the PK of PC14586 in Healthy Japanese Volunteers | |
| Phase 1Completed | 30 Nov 2022 | AME Study of [14C]-PC14586 in Healthy Male Participants | |
| Phase 1Completed | 3 Nov 2023 | A Study to Investigate the Effects of Acid Reducing Agents on Pharmacokinetics of PC14586 in Healthy Participants | |
| Phase 1Completed | 22 Oct 2024 | A Study to Investigate the Effects of Itraconazole on the Pharmacokinetics of PC14586 in Healthy Participants |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026